Cara Brocklehurst

Experience

• 

  Merck Sharp and Dohme

  Oct 1998 - Aug 1999

  Placement student
• 

  Novartis Institutes for BioMedical Research (NIBR)

  Aug 2005 - now

  What if we could develop an integrated drug discovery platform to accelerate drug discovery, which utilises micro-scale chemistry, real-time biological and physicochemical characterisation and machine learning driven compound design? At NIBR this is a reality! Our automated medicinal chemistry ‘design-make-test-analyse’ cycle is powered by machine learning, enables sequential multi-parameter optimisation and generates knowledge in a timeframe never before possible. We have built MicroCycle; a modular technology platform which benefits from recent advances in plate based micro-scale chemistry, micropurification, in-situ quantification and machine learning thus ensuring rapid access to high quality chemical matter already formatted for assay. Furthermore, by reorienting existing high throughput assay technology we can generate a full package of relevant data on each set of compounds in every learning cycle. Show less

  • Director, Head SynTech Basel

    Oct 2018 - now

  • Genesis Microcycle Team leader

    Jan 2018 - now

  • Scientific Team Leader - Synthesis & Technologies

    Jan 2015 - Dec 2017

  • Investigator III Prep Labs

    Aug 2005 - Dec 2014
• 

  Novartis Biomedical Research

  Oct 2023 - now

  Executive Director, Global Head of Synthetic Technologies